Anbio Biotechnology Class A Ordinary Shares (NNNN) - Total Liabilities
Based on the latest financial reports, Anbio Biotechnology Class A Ordinary Shares (NNNN) has total liabilities worth $153.92K USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Anbio Biotechnology Class A Ordinary Sha (NNNN) cash conversion ratio to assess how effectively this company generates cash.
Anbio Biotechnology Class A Ordinary Shares - Total Liabilities Trend (2021–2024)
This chart illustrates how Anbio Biotechnology Class A Ordinary Shares's total liabilities have evolved over time, based on quarterly financial data. Check NNNN financial resilience to evaluate the company's liquid asset resilience ratio.
Anbio Biotechnology Class A Ordinary Shares Competitors by Total Liabilities
The table below lists competitors of Anbio Biotechnology Class A Ordinary Shares ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cadre Holdings Inc
NYSE:CDRE
|
USA | $452.23 Million |
|
Pharming Group NV
NASDAQ:PHAR
|
USA | $178.15 Million |
|
Darma Henwa Tbk
JK:DEWA
|
Indonesia | Rp5.16 Trillion |
|
Aavas Financiers Limited
NSE:AAVAS
|
India | Rs147.61 Billion |
|
Mitra Adiperkasa Tbk
JK:MAPI
|
Indonesia | Rp14.63 Trillion |
|
Adtran Networks SE
F:ADV
|
Germany | €270.47 Million |
|
Zhejiang Taihua New Material
SHG:603055
|
China | CN¥6.37 Billion |
|
Shenzhen SEG Co Ltd
SHE:000058
|
China | CN¥2.53 Billion |
Liability Composition Analysis (2021–2024)
This chart breaks down Anbio Biotechnology Class A Ordinary Shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see NNNN company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 211.10 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.00 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.00 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Anbio Biotechnology Class A Ordinary Shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Anbio Biotechnology Class A Ordinary Shares (2021–2024)
The table below shows the annual total liabilities of Anbio Biotechnology Class A Ordinary Shares from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.73 Million | +74.23% |
| 2023-12-31 | $993.06K | -29.63% |
| 2022-12-31 | $1.41 Million | -40.70% |
| 2021-12-31 | $2.38 Million | -- |
About Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcript… Read more